BIOAVAILABILITY OF GLI/METXR (4/850 mg)

Healthy Clinical Trial

— GLMT12-SIL  

Official title:

Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) in Healthy Mexican Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01437800
• Other study ID #: GLMT12-SIL
• Status: Completed
• Phase: Phase 1
• Start date: January 2011
• Est. completion date: March 2011

Study information

• Verified date: May 2021
• Source: Laboratorios Silanes S.A. de C.V.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Objective:

The purpose of this study is to evaluate the oral bioavailability of the combination Glimepiride/ extended release Metformin (GLI/METXR) (4/850mg) in healthy Mexican volunteers in fasting conditions.

Methods: A prospective, longitudinal, open label, non randomized study, was performed, 24 volunteers were administrated with a single oral dose of GLI/METXR (4/850 mg).

Description:

Blood samples were collected over 30 hours. Plasma concentration of both drugs were measured by using high-performance liquid chromatography (HPLC). Plasma concentration-time curves were plotted for each volunteer, and pharmacokinetic parameters (PK) were calculated. the pharmacokinetic parameters to be determined are: Cmax, Tmax, AUC0-t, AUC0-inf, TMR, Ke, T1 / 2 of glimepiride and metformin Adverse events were determined using clinical and laboratory test results, throughout the study. The statistical analysis will be descriptive for plasma concentrations with respect to time and the pharmacokinetic parameters of Cmax, Tmax, AUC0-t, AUC0-inf, TMR, Ke, T1/2 of glimepiride and metformin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: March 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Healthy Mexican volunteers, considered healthy according to standard screening assessments

• Aged between 18 and 50 years old

• Body mass index (BMI) was 18 to 27.5

Exclusion Criteria:

• Those with a history or evidence of cardiovascular, renal, hepatic, gastrointestinal, neurologic, muscular, metabolic, or hematologic abnormality

• Any acute or chronic disease

• Any drug allergy and female volunteers positive to urinary pregnancy test or breastfeeding

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Glimepiride / Extended release Metformin (4/850 mg).
One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.

Locations

Country	Name	City	State
Mexico	Investigacion Farmacologica Y Biofarmaceutica, S.A. de C.V.	México

Sponsors (2)

Lead Sponsor	Collaborator
Laboratorios Silanes S.A. de C.V.	Instituto Mexicano del Seguro Social

Country where clinical trial is conducted

Mexico, 

References & Publications (5)

Badian M, Korn A, Lehr KH, Malerczyk V, Waldhäusl W. Determination of the absolute bioavailability of glimepiride (HOE 490), a new sulphonylurea. Int J Clin Pharmacol Ther Toxicol. 1992 Nov;30(11):481-2. — View Citation

Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996 Feb 29;334(9):574-9. Review. — View Citation

Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother. 1998 Oct;32(10):1044-52. Review. — View Citation

Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997 Jan;102(1):99-110. Review. — View Citation

DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999 Aug 17;131(4):281-303. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic Profile	Cmax, Area Under Curve, Tmax	Predose,0.25, 0.5, 0.75, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16,20, 24 y 30 hours post-dose
Secondary	Adverse events	Any change in health or undesirable experience in volunteers related or unrelated with the experimental drug.; Adverse events were determined using clinical and laboratory test results, throughout the study.	0.25, 0.5, 0.75, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16,20, 24 y 30 hours post-dose